These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31392195)

  • 21. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study.
    Tardieu M; Cudejko C; Cano A; Hoebeke C; Bernoux D; Goetz V; Pichard S; Brassier A; Schiff M; Feillet F; Rollier P; Mention K; Dobbelaere D; Fouilhoux A; Espil-Taris C; Eyer D; Huet F; Walther-Louvier U; Barth M; Chevret L; Kuster A; Lefranc J; Neveu J; Pitelet G; Ropars J; Rivier F; Roubertie A; Touati G; Vanhulle C; Tardieu E; Caillaud C; Froissart R; Champeaux M; Labarthe F; Chabrol B
    Eur J Neurol; 2023 Sep; 30(9):2828-2837. PubMed ID: 37235686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.
    Brassier A; Pichard S; Schiff M; Bouchereau J; Bérat CM; Caillaud C; Pion A; Khraiche D; Fauroux B; Oualha M; Barnerias C; Desguerre I; Hully M; Maquet M; Deladrière E; de Lonlay P; Gitiaux C
    Mol Genet Metab; 2023 Aug; 139(4):107650. PubMed ID: 37454519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center.
    Kim MS; Song A; Im M; Huh J; Kang IS; Song J; Yang A; Kim J; Kwon EK; Choi EJ; Han SJ; Park HD; Cho SY; Jin DK
    Korean J Pediatr; 2019 Jun; 62(6):224-234. PubMed ID: 30360039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype.
    Lee DH; Qiu WJ; Lee J; Chien YH; Hwu WL
    JIMD Rep; 2014; 17():71-5. PubMed ID: 25213570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Timely Needs for Infantile Onset Pompe Disease Newborn Screening-Practice in Taiwan.
    Chiang SC; Chien YH; Chang KL; Lee NC; Hwu WL
    Int J Neonatal Screen; 2020 Jun; 6(2):30. PubMed ID: 33073026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.
    Yoshida T; Awaya T; Jonouchi T; Kimura R; Kimura S; Era T; Heike T; Sakurai H
    Sci Rep; 2017 Oct; 7(1):13473. PubMed ID: 29044175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.
    Byrne BJ; Fuller DD; Smith BK; Clement N; Coleman K; Cleaver B; Vaught L; Falk DJ; McCall A; Corti M
    Ann Transl Med; 2019 Jul; 7(13):290. PubMed ID: 31392202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History.
    Lecis M; Rossi K; Guerzoni ME; Mariotti I; Iughetti L
    Case Rep Pediatr; 2023; 2023():8470341. PubMed ID: 36845322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and challenges of gene therapy for Pompe disease.
    Ronzitti G; Collaud F; Laforet P; Mingozzi F
    Ann Transl Med; 2019 Jul; 7(13):287. PubMed ID: 31392199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractures in children with Pompe disease: a potential long-term complication.
    Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
    Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years.
    Schänzer A; Görlach J; Claudi K; Hahn A
    Neuromuscul Disord; 2019 Jun; 29(6):477-482. PubMed ID: 31101460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.
    Buckley AF; Desai AK; Ha CI; Petersen MA; Estrada JC; Waterfield JR; Bossen EH; Kishnani PS
    J Neuropathol Exp Neurol; 2023 Mar; 82(4):345-362. PubMed ID: 36864705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis.
    Dornelles AD; Junges APP; Krug B; Gonçalves C; de Oliveira Junior HA; Schwartz IVD
    Front Pediatr; 2024; 12():1310317. PubMed ID: 38425665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management.
    Bolano-Diaz C; Diaz-Manera J
    Ther Clin Risk Manag; 2022; 18():1099-1115. PubMed ID: 36536827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.